Project Grant R56HL173608
Award Date
9/24/24
Completion Date
8/31/25
Dollars Obligated
$507K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $119,250 to the University of Pittsburgh to research the role of METTL14-mediated mRNA methylation in postnatal cardiac development and maturation. The project aims to investigate how METTL14-regulated mRNA modifications govern the transcriptional programs that control cardiomyocyte proliferation, differentiation, and maturation, with a...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to model cell-specific signaling of the LRP1 receptor in the context of acute myocardial infarction (AMI) and associated heart failure. The research aims to expand and validate signaling networks that predict how early cardiomyocyte LRP1 signaling enhances cell survival after ischemia-reperfusion, as well as how late...
This Project Grant award of $1,602,792 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a study on the "Phenotypic Consequences of Lipoprotein(a) in Diverse Populations." The study aims to address gaps in understanding the effects of lipoprotein(a), a causal cardiovascular disease risk factor, across diverse populations. The key research activities include: Assembling a large, ancestrally diverse...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), provides $1,137,498 to conduct research under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award aims to decipher the regulatory mechanisms involved in cardiac maturation, with the goal of understanding the genetic origins of heart disease, developing new heart failure therapeutics, and optimizing cardiomyocyte regeneration...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to identify transcriptional regulators of endocardial-specific gene expression and understand how these regulate heart development, homeostasis, and regeneration. The award, totaling $540,856.00 and spanning from December 2024 to November 2028, will be conducted by the Regents of the University of California, San...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $802,762 to The University of Texas Southwestern Medical Center to conduct research on interpreting the impact of genetic variants, both coding and non-coding, on congenital heart disease. The research aims to define cardiac gene regulatory networks, characterize genetic variants that regulate cardiac gene programs, and assess the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $487,567 to Indiana University to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects (CHDs). The research aims to identify genetic variants and biological pathways associated with CHDs, as well as build predictive models leveraging genetic, epigenetic,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $168,480 to Ann & Robert H. Lurie Children's Hospital of Chicago to conduct research on prenatal care utilization and postnatal outcomes for publicly insured children with congenital heart defects. The key objectives of this research project are to: 1) identify common prenatal care utilization pathways leading to delivery at a...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to investigate the mechanisms linking persistent DNA damage to the upregulation of NLRP12 and the functional implications in aging hematopoiesis. The total funding amount for this award is $1,419,308.00, with a project period from September 17, 2024 to August 31, 2025. The project aims to elucidate the novel...
This $756,039 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to understand the impact of regulatory genetic variants on the severity of cardiomyopathies caused by haploinsufficiency genes, such as MYBPC3 and DSP. The 5-year project, led by researchers at the University of Michigan, will use human induced pluripotent stem cell cardiomyocytes and mouse models to quantify the...